Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Nymox Pharmaceutical Corporation (NYMX)

0.2863   -0.01 (-3.34%) 12-02 15:59
Open: 0.2961 Pre. Close: 0.2962
High: 0.2962 Low: 0.28
Volume: 167,540 Market Cap: 26(M)

Technical analysis

as of: 2022-12-02 4:25:01 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.39     One year: 0.44
Support: Support1: 0.28    Support2: 0.23
Resistance: Resistance1: 0.34    Resistance2: 0.37
Pivot: 0.31
Moving Average: MA(5): 0.3     MA(20): 0.31
MA(100): 0.37     MA(250): 0.84
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 6.8     %D(3): 10
RSI: RSI(14): 34.1
52-week: High: 2.09  Low: 0.18
Average Vol(K): 3-Month: 71 (K)  10-Days: 52 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NYMX ] has closed below the lower bollinger band by 4.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 63.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 27 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.3 - 0.3 0.3 - 0.3
Low: 0.27 - 0.28 0.28 - 0.28
Close: 0.28 - 0.29 0.29 - 0.29

Company Description

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.

Headline News

Fri, 25 Nov 2022
May 2023 Market Cap Requirement Update - Nymox Pharmaceutical (NASDAQ:NYMX) - Benzinga

Sun, 09 Oct 2022
Insiders might want to re-evaluate their US$1.9m stock purchase as Nymox Pharmaceutical Corporation (NASDAQ:NYMX) drops to US$32m - Simply Wall St

Tue, 13 Sep 2022
NYMOX Provides Current Update - GlobeNewswire

Wed, 17 Aug 2022
Is Nymox Pharmaceutical (NASDAQ:NYMX) In A Good Position To Deliver On Growth Plans? - Simply Wall St

Fri, 15 Jul 2022
NYMOX Updates Shareholders - GlobeNewswire

Wed, 25 May 2022
Nymox tanks as FDA rejects NDA for fexapotide - The Pharma Letter

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 91 (M)
Shares Float 51 (M)
% Held by Insiders 45 (%)
% Held by Institutions 0.8 (%)
Shares Short 1,820 (K)
Shares Short P.Month 1,760 (K)

Stock Financials

EPS -0.19
EPS Est Next Qtl 0
EPS Est This Year -0.21
EPS Est Next Year -0.57
Book Value (p.s.) 0.01
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -145.2
Return on Equity (ttm) -284.1
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.15
Qtrly Earnings Growth 0
Operating Cash Flow -8 (M)
Levered Free Cash Flow -6 (M)

Stock Valuations

PE Ratio -1.57
PEG Ratio 0
Price to Book value 14.31
Price to Sales 0
Price to Cash Flow -3.31

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.